Acute eosinophilic hepatitis from trovafloxacin.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  New England Journal of Medicine

• Publication date

  2000-02-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM200002033420517PMID 10660405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Autoantibodies against a kidney--liver protein associated with quinolone-induced acute interstitial nephritis or hepatitis.

  1997cited by this paper
• Antibiotic-Associated Hepatitis: Update from 1990

  1997cited by this paper
• Hepatotoxicity of antibiotics.

  1995cited by this paper

• Novel Naphthyridones Targeting Pannexin 1 for Colitis Management

  2024cites this paper
• The Role of Eosinophils in Liver Disease

  2024cites this paper
• The Risk of Hepatotoxicity with Fluoroquinolones: A National The Risk of Hepatotoxicity with Fluoroquinolones: A National Case-Control Safety Study Case-Control Safety Study

  2023cites this paper
• TNFα enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy.

  2021cites this paper
• Drug‐Metabolism Enzymes and Transporter Activities as Risk Factors of Selected Marketed Drugs Associated with Drug‐Induced Fatalities

  2021cites this paper
• A comparative study of effect of fluoroquinolones on blood glucose levels in rats

  2020cites this paper
• INTERNATIONAL SEVERE WARNING REQUIREMENTS AND SMART DECISIONS IN CHOICE TACTICS FOR FLUOROQUINOLONES

  2020cites this paper
• Quinolone antibiotics

  2019cites this paper
• Ameliorative effects of Moringa oleifera leaf extract on levofloxacin-induced hepatic toxicity in rats

  2019cites this paper
• Drugs and Toxins

  2018cites this paper
• Ecopharmacokinetics and Ecopharmacodynamics of PPCPs

  2018cites this paper
• Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review

  2017cites this paper
• The Risk of Hepatotoxicity with Fluoroquinolones : A National Case-Control Safety Study

  2016cites this paper
• Differential Effects of Trovafloxacin on TNF-α and IL-6 Profiles in a Rat Hepatocyte–Kupffer Cell Coculture System

  2015cites this paper
• Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.

  2014cites this paper
• The Mechanisms of Action and Resistance to Fluoroquinolone in Helicobacter pylori Infection

  2014cites this paper
• Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges

  2014cites this paper
• EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars

  2013cites this paper
• Eosinophils mediate the pathogenesis of halothane‐induced liver injury in mice

  2013cites this paper
• Hepatotoxicity of Antimicrobials and Antifungal Agents

  2013cites this paper
• Hepatotoxicity of antibiotics: a review and update for the clinician.

  2013cites this paper
• 13 – Hepatic injury due to drugs, herbal compounds, chemicals and toxins

  2012cites this paper
• Interrogating a range of biological targets using chemical biology

  2012cites this paper
• Review of the Quinolone Family

  2012cites this paper
• Idiosyncratic Drug Reactions and the Potential Role of Metabolism

  2012cites this paper
• Fluoroquinolones Reported Hepatotoxicity

  2012cites this paper
• Clinical and histopathologic features of fluoroquinolone-induced liver injury.

  2011cites this paper
• Eosinophilic Infiltration of the Liver and Pancreas Mimicking Metastatic Disease

  2010cites this paper
• Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

  2010cites this paper
• The Internist's Literature on Chronic Rhinosinusitis: An Evaluation of the Amount and Quality of Published Information

  2010cites this paper
• Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages

  2010cites this paper
• Newer, Discontinued Fluoroquinolones: Temafloxacin, Trovafloxacin, Grepafloxacin and Clinafloxacin

  2010cites this paper
• Drug-induced hepatotoxicity or drug-induced liver injury.

  2009cites this paper
• Tumor Necrosis Factorα Is a Proximal Mediator of Synergistic Hepatotoxicity from Trovafloxacin/Lipopolysaccharide Coexposure

  2009cites this paper
• Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin

  2009cites this paper
• Drotrecogin alfa activated in clinical practice and the current evidences.

  2008cites this paper
• An overview of harms associated with β-lactam antimicrobials: where do the carbapenems fit in?

  2008cites this paper
• Post-Marketing Surveillance of the Safety of Levofloxacin in Japan

  2007cites this paper
• Miscellaneous antibacterial drugs

  2007cites this paper
• Hypersensitivity reactions to quinolones.

  2006cites this paper
• Antimicrobial Agents with Improved Clinical Efficacy versus Their Persistence in the Environment: Synthetic 4-Quinolone As an Example

  2005cites this paper
• Adverse drug reactions in the ICU: lessons learned.

  2005cites this paper
• Quinolones in 2005: an update.

  2005cites this paper
• A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.

  2004cites this paper
• Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.

  2004cites this paper
• Treatment of experimental bacterial keratitis with topical trovafloxacin.

  2004cites this paper
• Development of the quinolones.

  2003cites this paper
• Eotaxins and IL-5 and Recruiting Leukocytes Cell-Mediated Hepatitis: Up-Regulating Crucial Role of IL-4/STAT6 in T

  2003cites this paper
• Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.

  2003cites this paper
• Quinolone hypersensitivity

  2003cites this paper
• Adverse drug reactions: implications for the development of fluoroquinolones.

  2003cites this paper
• Crucial Role of IL-4/STAT6 in T Cell-Mediated Hepatitis: Up-Regulating Eotaxins and IL-5 and Recruiting Leukocytes

  2003cites this paper
• Growth hormone prevents human immunodeficiency virus–induced neuronal p53 expression

  2003cites this paper
• Hepatotoxicity of antibiotics and antifungals.

  2003cites this paper
• The quinolones: decades of development and use.

  2003cites this paper
• Fulminant liver disease.

  2003cites this paper
• Safety of fluoroquinolones: An update.

  2002cites this paper
• Possible Gatifloxacin-Induced Fulminant Hepatic Failure

  2002cites this paper
• Critical role of interleukin 5 and eosinophils in concanavalin A-induced hepatitis in mice.

  2002cites this paper
• Moxifloxacin-induced acute liver injury

  2002cites this paper
• Medication adherence and the physician-patient relationship

  2002cites this paper
• Moxifloxacin-induced acute liver injury.

  2002cites this paper
• Chronic hepatitis C, ibuprofen, and liver damage

  2002cites this paper
• Drug-Drug Interactions: Toxicological Perspectives

  2001cites this paper
• Structure toxicity relationships--how useful are they in predicting toxicities of new drugs?

  2001cites this paper
• New Milestones Achieved in Fluoroquinolone Safety

  2001cites this paper
• Drug-induced liver disease.

  2001cites this paper
• CASE REPORT: Trovafloxacin Hepatotoxicity

  2001cites this paper
• Acute liver failure.

  2001cites this paper
• Gatifloxacin‐Associated Acute Hepatitis

  2001cites this paper
• Use of the Quinolones in Pediatrics

  2000cites this paper
• Drug induced liver disease

  2000cites this paper
• Drug-induced liver disease

  2000cites this paper
• Chapter 14 – Safety Overview: Toxicity, Adverse Effects, and Drug Interactions

  2000cites this paper
• Trovafloxacin hepatotoxicity

  2000cites this paper
• Terms and Conditions for Use of Pdf

  year unknowncites this paper